-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VivrSq6V02ksyD9iKvFOujernPUI9yG/AkR7Y/fGvCqU7ybkbZ2p4DQhgKE0UJLD K6LnbFA5QXvKUsCrn+Bsaw== 0000950135-96-003740.txt : 19960819 0000950135-96-003740.hdr.sgml : 19960819 ACCESSION NUMBER: 0000950135-96-003740 CONFORMED SUBMISSION TYPE: 10-C PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19960814 FILED AS OF DATE: 19960816 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-C SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 96617061 BUSINESS ADDRESS: STREET 1: 40 ALLSTON ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6175763111 10-C 1 VERTEX PHARMACEUTICALS INCORPORATED 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-C REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ INTERDEALER QUOTATION SYSTEM FILED PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULES 13a-17 AND 15d-17 THEREUNDER Vertex Pharmaceuticals Incorporated - -------------------------------------------------------------------------------- (Exact name of issuer as specified in charter) 130 Waverley Street - -------------------------------------------------------------------------------- (Address of principal executive offices) Issuer's telephone number, including are code (617) 577-6000 ----------------------------------- I. CHANGE IN NUMBER OF SHARES OUTSTANDING Indicate any change (increase or decrease) of five percent or more in the number of shares outstanding: 1. Title of security Common Stock, $.01 par value per share ------------------------------------------------------------ 2. Number of shares outstanding before the change 17,358,458 ------------------------------- 3. Number of shares outstanding after the change 20,808,458 -------------------------------- 4. Effective date of change August 14, 1996 ----------------------------------------------------- 5. Method of change: Specify method (such as merger, acquisition, exchange, distribution, stock split, reverse split, acqusition of stock for treasury, etc.) Public Offering --------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Give brief description of transaction 3,450,000 shares of Common Stock sold --------------------------------------- in a firm underwritten public offering --------------------------------------- II. CHANGE IN NAME OF ISSUER 1. Name prior to change --------------------------------------------------------- 2. Name after change ------------------------------------------------------------ 3. Effective date of charter amendment changing name ---------------------------- 4. Date of shareholder approval of change, if required -------------------------- Date August 15, 1996 /s/ Thomas G. Auchincloss, Jr. --------------------------- ----------------------------------------- Senior Director of Finance and Treasurer ----------------------------------------- (Officer's signature and title) -----END PRIVACY-ENHANCED MESSAGE-----